Ciclesonide
سیکلزونید
🌬️ Respiratory SystemInhaled corticosteroid
Market / country: 🇺🇸 USA
Alvesco (US)
🧮 Dose calculator
Asthma and chronic lung disease (reversible airflow obstruction) · Regimen source: FDA Alvesco · 2.2, Table 1
- • Bronchodilators alone before: max 160 mcg twice; prior ICS: up to 320; oral steroids: 320 mcg twice. Rinse mouth after use. FDA Alvesco · 2.2, Table 1FDA Alvesco · 2.1
Enter age (weight is optional for this regimen).
🛡️ Safety & information
Contraindications
- ⛔ Primary treatment of status asthmaticus or acute episodes; hypersensitivity to ciclesonide. FDA Alvesco · 4
Warnings
- • Oral candidiasis; not for acute episodes; immunosuppression; adrenal suppression when switching from oral steroids; reduced bone density; effect on growth; glaucoma and cataract. FDA Alvesco · 5
Formulations
- 80 mcg per actuation — inhaler 🇺🇸 USA FDA Alvesco · 3
- 160 mcg per actuation — inhaler 🇺🇸 USA FDA Alvesco · 3
👥 Special populations
- 🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Alvesco · 8.1
“Risk Summary There are no available data on ALVESCO use in pregnant women to assess a drug associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.”
- 🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Alvesco · 8.2
“Risk Summary There are no data on the presence of ciclesonide or its metabolite in human milk, the effects on the breastfed infant, or the effects on milk production.”
- 👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Alvesco · 8.4
“The safety and effectiveness of ALVESCO for the maintenance treatment of asthma as prophylactic therapy have been established in pediatric patients aged 12 years and older.”
- 👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Alvesco · 8.5
“In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy.”
- ⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.
🔗 Reference links
- FDA (approval record)NDA021658
- DailyMed (FDA label)FDA Alvesco
- MedlinePlus (NIH)Ciclesonide Nasal SprayCiclesonide Oral Inhalation
- WHO ATC/DDDR03BA08
- Darooyab (Iran)❌ None
🇮🇷 Not found in Iran list Darooyab · search
Darooyab lists no registered dosage form or brand for this drug. This does not prove it is unavailable.
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Alvesco · 3FDA Alvesco · 2.2, Table 1FDA Alvesco · 2.1FDA Alvesco · 4FDA Alvesco · 5FDA Alvesco · SPL approval / marketing categoryFDA Alvesco · 8.1FDA Alvesco · 8.2FDA Alvesco · 8.4FDA Alvesco · 8.5
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · search
- Clinical review⚠ Unverified